Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.1771
Abstract: We report the population pharmacokinetic (PK) and exposure‐response analyses of a novel subcutaneous formulation of daratumumab (DARA) using data from 3 DARA subcutaneous monotherapy studies (PAVO Part 2, MMY1008, COLUMBA) and 1 combination therapy study… read more here.
Keywords: exposure response; intravenous dara; dara; monotherapy ... See more keywords
Daratumumab induces CD38 internalization and impairs myeloma cell adhesion
Sign Up to like & getrecommendations! Published in 2018 at "OncoImmunology"
DOI: 10.1080/2162402x.2018.1486948
Abstract: ABSTRACT Daratumumab (Dara), a human immunoglobulin G1 kappa (IgG1κ) monoclonal anti-CD38 antibody, has been approved by the U.S. Food and Drug Administration for the treatment of relapsed multiple myeloma (MM) as a single agent as… read more here.
Keywords: myeloma; cell adhesion; dara; cell ... See more keywords
High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-003804
Abstract: Background Adoptive transfer of natural killer (NK) cells with augmented antibody-dependent cellular cytotoxicity (ADCC) capabilities and resistance to CD38 targeting has the potential to enhance the clinical anti-myeloma activity of daratumumab (DARA). Therefore, we sought… read more here.
Keywords: cd16; cd38; activity; cd38 locus ... See more keywords
Long-Lasting Remissions for Myeloma Patients on Daratumumab Therapy from the GEN501 and GEN503 Trials
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-111095
Abstract: Introduction The first two trials to test the activity of daratumumab (DARA) in relapsed/refractory multiple myeloma (MM) were GEN501 (DARA monotherapy) and GEN503 (DARA in combination with lenalidomide [LEN] and dexamethasone [DEX]). GEN501 enrolled 104… read more here.
Keywords: therapy; dara; gen501 gen503; dara therapy ... See more keywords
Increasing Daratumumab Frequency As a Way to Restore Responses- a Retrospective Case Study
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-119589
Abstract: Introduction: Multiple Myeloma (MM) remains difficult to treat despite significant advances in treatment options. Daratumumab (dara) as a single-agent or in combination with other treatments has considerable efficacy even among patients with highly-refractory disease. However,… read more here.
Keywords: following cycle; frequency; treatment; dara ... See more keywords
Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-123405
Abstract: Introduction: The intravenous (IV) formulation of human CD38 mAb DARA is approved in many countries as monotherapy or in combination with standard-of-care regimens for treatment of multiple myeloma (MM). To reduce patient (pt)/provider burden and… read more here.
Keywords: board directors; dara; membership entity; janssen employment ... See more keywords
Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-123446
Abstract: Hui-qiang Huang and Won-Seog Kim contributed equally to this work. Introduction: NKTCLs are rare, Epstein-Barr virus-associated distinct subtypes of peripheral T-cell lymphoma. These are primarily extranodal and of the nasal type and are more common… read more here.
Keywords: dara; monotherapy; response; research funding ... See more keywords
CD38 Knockout Primary NK Cells to Prevent "Fratricide" and Boost Daratumumab Activity
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-129456
Abstract: Multiple myeloma (MM) is a plasma cell neoplasm typically characterized by high and uniform CD38 expression. Daratumumab (DARA), a humanized monoclonal antibody targeting CD38 has dramatically improved the outcome of patients with refractory MM, but… read more here.
Keywords: cd38ko cells; primary cells; dara; cd38 ... See more keywords
Pattern of Use and Efficacy of Daratumumab-Based Therapy in Patients with AL Amyloidosis: A Single Institution Experience
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-139643
Abstract: Introduction: Light chain Amyloidosis (AL) is a systemic disease caused by abnormal clonal plasma cells which produce excessive light chains that further misfold and deposit into vital organs. Currently, treatment options for AL amyloidosis are… read more here.
Keywords: response; time; efficacy; dara ... See more keywords
Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-140270
Abstract: Antibody application is a promising therapy in hematological malignancies including acute lymphoblastic leukemia (ALL). Unlike for B-cell precursor (BCP-ALL), immunotherapeutic interventions in T-cell ALL (T-ALL) are practically non-existent. Most T-ALL patient samples show substantial surface… read more here.
Keywords: hu5f9 igg2; phagocytosis; cd47; dara ... See more keywords
Progression Free Survival (PFS) Analysis of Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients
Sign Up to like & getrecommendations! Published in 2021 at "Blood"
DOI: 10.1182/blood-2021-150607
Abstract: Background: Newly drugs access for MM treatment still a challenge in some countries. One of the most available inductions for TE NDMM patients (pts) worldwide is cyclophosphamide (C), thalidomide (T) and dexamethasone (d)-(CTd). Dara the… read more here.
Keywords: analysis; treatment; pfs; dara ... See more keywords